Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCERTO: Bacterial Decolonization and ICG Angiography for Lower Extremity Soft Tissue Sarcomas
NCT06712433Phase 2Withdrawn
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mupirocin and chlorhexidine in Postoperative wound complications and radiation dermatitis. Primary endpoint: Incidence and type of acute major wound complications up to 24 months. Planned start Sep 2026; status: withdrawn.
02
Drugs
mupirocinchlorhexidine
03
Conditions
Postoperative wound complicationsradiation dermatitis
Beyond the preview
Go deeper on NCT06712433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712433.